Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed. With the busy holiday season and the winter ...

The Korea Institute of Science and Technology (KIST) has entered into a technology transfer agreement with Huons BioPharma for the development and commercialization of a peptide treatment for dry ...

Jacques Gilbert has been appointed Chief Strategy and Business Development Officer for Topcon Healthcare Inc. According to the company, Jacques will lead the development and execution of Topcon ...

The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully ...

A large international study conducted by the LHON Study Group reported that a unilaterally administered gene therapy to treat Leber hereditary optic neuropathy (LHON) caused by the MT-ND4 gene variant ...

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging AAV.SPR capsid for central retina transduction without foveal detachment risks.

Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating ...